Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
ViewRay's peak revenue was $102.2M in 2022. The peak quarterly revenue was $34.7M in 2022(q4).
ViewRay's revenue increased from $3.2m in 2013 to $102.2M currently. That's a 3,135.39% change in annual revenue.
| Fiscal year / year | ViewRay revenue |
|---|---|
| 2013 | $3.2M |
| 2014 | $6.4M |
| 2015 | $10.4M |
| 2016 | $22.2M |
| 2017 | $34.0M |
| 2018 | $81.0M |
| 2019 | $87.8M |
| 2020 | $57.0M |
| 2021 | $70.1M |
| 2022 | $102.2M |
How accurately did ViewRay's revenue projections match actual performance?
ViewRay saw the greatest revenue growth in 2018, when revenue increased by 137.83%.
ViewRay had the lowest revenue growth in 2020, when revenue changed by -35.05%.
| Year | ViewRay growth |
|---|---|
| 2014 | 103%↑ |
| 2015 | 62%↑ |
| 2016 | 114%↑ |
| 2017 | 53%↑ |
| 2018 | 138%↑ |
| 2019 | 8%↑ |
| 2020 | -35%↓ |
| 2021 | 23%↑ |
| 2022 | 46%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2015 | - | - | $5.3M | $4.6M |
| 2016 | $5.5M | $299,000 | $357,000 | $16.1M |
| 2017 | $1.2M | $698,000 | $12.2M | $19.9M |
| 2018 | $26.2M | $16.4M | $17.7M | $20.7M |
| 2019 | $20.3M | $30.2M | $20.9M | $16.5M |
| 2020 | $14.3M | $14.2M | $10.1M | $18.5M |
| 2021 | $15.5M | $15.0M | $19.2M | $20.4M |
| 2022 | $18.9M | $22.1M | $26.5M | $34.7M |
| 2023 | $22.5M | - | - | - |
Do you work at ViewRay?
Did ViewRay meet its revenue projections?
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 221 |
| Date Founded | 2004 |
| Headquarters | Bedford, Ohio |
| Number of Locations | 3 |
| Revenue | $102.2M |
| Net Income | -$107,330,000 |
| Gross Proft | $10.0M (2022) |
| Tax Rate | -0.0% |
| Total Assets | $271,397,000 |
| Ticker | VRAY |
ViewRay received early financing of $3.0M on 2007-08-08.
| Series | Round size | Date |
|---|---|---|
| Series A | $3M | 08/2007 |
| Series B | $25M | 01/2008 |
| Series C | $20M | 08/2010 |
| Debt Financing | $10M | 09/2011 |
| Series C | $45M | 03/2012 |
| Series Unknown | $15M | 05/2013 |
| Series Unknown | $30M | 12/2013 |
| Series C | $16.3M | 01/2015 |
| Series Unknown | $15M | 03/2015 |
| Post Ipo Debt | $50M | 06/2015 |
| Post Ipo Equity | $26.7M | 07/2015 |
| Post Ipo Equity | $2.7M | 08/2015 |
| Post Ipo Equity | $14M | 08/2016 |
| Post Ipo Equity | $26.1M | 01/2017 |
| Post Ipo Equity | $50M | 10/2017 |
| Post Ipo Equity | $59M | 02/2018 |
| Post Ipo Equity | $172.5M | 08/2018 |
| Debt Financing | $56M | 01/2019 |
| Post Ipo Equity | $36M | 12/2019 |
| Post Ipo Equity | $80.5M | 11/2021 |
| Investors | Security type |
|---|---|
| Eight Roads Ventures | Series B |
| Kearny Venture Partners | Series B |
| F Prime Capital | Series B |
| OrbiMed Advisors | Series B |
| Aisling Capital | Series B |
| Next47 | Series C |
| Kearny Venture Partners | Series C |
| OrbiMed Advisors | Series C |
| F Prime Capital | Series C |
| Aisling Capital | Series C |
| Kearny Venture Partners | Debt Financing |
| Next47 | Debt Financing |
| OrbiMed Advisors | Debt Financing |
| F Prime Capital | Debt Financing |
| Aisling Capital | Debt Financing |
| Next47 | Series C |
| Kearny Venture Partners | Series C |
| OrbiMed Advisors | Series C |
| F Prime Capital | Series C |
| Aisling Capital | Series C |
| Kearny Venture Partners | Series Unknown |
| Next47 | Series Unknown |
| OrbiMed Advisors | Series Unknown |
| F Prime Capital | Series Unknown |
| Aisling Capital | Series Unknown |
| Kearny Venture Partners | Series Unknown |
| OrbiMed Advisors | Series Unknown |
| F Prime Capital | Series Unknown |
| HERCULES CAPITAL INC | Series Unknown |
| Aisling Capital | Series Unknown |
| CRG LP | Post Ipo Debt |
| Montrose Capital Partners | Post Ipo Equity |
| Xeraya Capital | Post Ipo Equity |
| Kearny Venture Partners | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| Fidelity Investments | Post Ipo Equity |
| Aisling Capital | Post Ipo Equity |
| Xeraya Capital | Post Ipo Equity |
| Kearny Venture Partners | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| Puissance Capital | Post Ipo Equity |
| Acuta Capital Partners | Post Ipo Equity |
| Kearny Venture Partners | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| Armentum Partners | Debt Financing |
| Elekta | Post Ipo Equity |
ViewRay's top competitor, ASML Holding, earned an annual revenue of $11.8B.
ViewRay's smallest competitor is Clarity Medical Systems with revenue of $6.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Accuray | $80,135 | $446.6M | 947 | 30 |
| Nanometrics | $91,487 | $987.3M | 551 | - |
| Axcelis Technologies | $68,544 | $1.0B | 1,004 | 30 |
| Clarity Medical Systems | $47,907 | $6.5M | 55 | - |
| Loral Data Systems | $51,437 | $820.5M | 21 | - |
| ASML Holding | $98,673 | $11.8B | 32,016 | 150 |
| Cymer | $87,104 | $538.6M | 1,301 | 1 |
| Ag Systems | $46,810 | $34.2M | 35 | - |
| Aehr Test Systems | $48,560 | $66.2M | 79 | 5 |
| Optivus | $46,976 | $17.6M | 50 | - |
Zippia gives an in-depth look into the details of ViewRay, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ViewRay. The employee data is based on information from people who have self-reported their past or current employments at ViewRay. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ViewRay. The data presented on this page does not represent the view of ViewRay and its employees or that of Zippia.
ViewRay may also be known as or be related to VIEWRAY INC., VIEWRAY TECHNOLOGIES, INC., ViewRay, ViewRay Inc, ViewRay Technologies Inc, ViewRay, Inc. and Viewray Incorporated.